1. Home
  2. FUND vs PROK Comparison

FUND vs PROK Comparison

Compare FUND & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$8.64

Market Cap

245.4M

Sector

Finance

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$2.22

Market Cap

417.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUND
PROK
Founded
1988
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.4M
417.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FUND
PROK
Price
$8.64
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
32.5K
1.2M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
6.64%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
N/A
$744,000.00
Revenue This Year
N/A
$918.66
Revenue Next Year
N/A
N/A
P/E Ratio
$8.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.75
$0.46
52 Week High
$8.47
$7.13

Technical Indicators

Market Signals
Indicator
FUND
PROK
Relative Strength Index (RSI) 55.13 42.40
Support Level $8.65 $2.09
Resistance Level $8.95 $2.29
Average True Range (ATR) 0.12 0.17
MACD 0.03 0.02
Stochastic Oscillator 61.18 28.69

Price Performance

Historical Comparison
FUND
PROK

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: